title: Icatibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors.
abstract: Angioedema related to the use of angiotensin-converting enzyme inhibitors (AE-ACEi) has, so far, been treated with antiallergic drugs with questionable results. Because angioedema in this setting is likely related to increased levels of bradikinin, we decided to use icatibant, a bradikinin receptor antagonist licensed for use in hereditary angioedema, in a patient with AE-ACEi. In the same patient, the time to resolution of the angioedema during previous attacks was about 2 days when classic antiallergic drug regimens were used; when icatibant was used, this time shortened to 10 hours. Icatibant is a promising drug in the treatment of AE-ACEi.
authors.affiliation: Department of Emergency Medicine, "Santi Giovanni e Paolo" Hospital, Venice, Italy. Electronic address: mauro.gallitelli@libero.it.
authors.forename: Mauro
authors.initials: M
authors.lastname: Gallitelli
authors.forename: Michele
authors.initials: M
authors.lastname: Alzetta
mesh_terms: D000368:Aged; D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065168:Bradykinin Receptor Antagonists; D006801:Humans; D017706:Lisinopril / Q000009:adverse effects; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D065168:Bradykinin Receptor Antagonists; C065679:icatibant; D017706:Lisinopril; D001920:Bradykinin